Table 1. Indication for donor search and allogeneic stem cell transplantation in chronic myeloid leukemia^*1.

	Following diagnosis	During disease course
HLA-typing of patient and search for family donor	AP or BC Mutation T315I Major route aberrations*2	Failure of first-line TKI Failure of two TKI Progress with AP, BC, or mutation T315I
Search for unrelated donor	Mutation T315I AP or BC	Failure of nilotinib or dasatinib as first-line TKI Failure of two TKI Progress with AP, BC, or mutation T315I
Indication for allogeneic SCT	Mutation T315I BC AP without optimal response to TKI	Failure of nilotinib or dasatinib as first-line TKI Failure of two TKI Progress with AP, BC, or mutation T315I

^*1A tiered approach is recommended, depending on initial risk constellation and disease course.

^*2Clonal chromosomal aberrations in Philadelphia chromosome-positive cells, e.g., trisomy 8, trisomy Ph (+der(22)t(9;22)(q34;q11)), isochromosome 17 (i(17)(q10)), trisomy 19 and ider(22)(q10)t(9;22)(q34;q11)

SCT, stem cell transplantation; HLA, human leukocyte antigen; AP, accelerated phase; BC, blast crisis; TKI, tyrosine kinase inhibitor(s)